Joplin Globe

BrYet US, Inc. Receives Approval to Initiate in Australia a First-in-Human Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement

HOUSTON, TX / ACCESS Newswire / October 6, 2025 / HOUSTON, TX and SUNSHINE COAST, QUEENSLAND / ACCESS Newswire / October 6, 2025 / BrYet US, Inc. ("BrYet"), a biotechnology innovator developing a drug ...
Finanznachrichten

Bryet US Inc: BrYet US, Inc. Receives Approval to Initiate in Australia a First-in-Human Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement

HOUSTON, TX and SUNSHINE COAST, QUEENSLAND / ACCESS Newswire / October 6, 2025 / BrYet US, Inc. ("BrYet"), a biotechnology innovator developing a drug with the potential to be a first-in-class ...
Detroit Free Press

BrYet US, Inc. Receives Approval to Initiate in Australia a First-in-Human Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement

The open-label, dose-escalation and expansion study, titled “A Phase 1/2 Study of ML-016 in Participants with Advanced Cancer with Lung and/or Liver Involvement,” is authorized to commence in ...